Biopharma insights | Kearney

Biotechnology: what China’s rise means for Europe

Healthcare and Life Sciences / Article / May 08, 2026
In conversation with Dr. Jörg Schüttrumpf

Biopharma R&D Practitioner Voices / Commentary / March 06, 2026
[w]Health Healthcare and Life Sciences Index

Research report / March 05, 2026
[w]Health Tech Manifesto: from ambition to impact with data, digital, and AI

[w]Health / Article / January 14, 2026
In conversation with Mark Travers

Biopharma R&D Practitioner Voices / Commentary / June 20, 2025
Five strategic responses to potential US tariffs on branded pharmaceuticals

Healthcare and Life Sciences / Article / May 16, 2025
The 2025 biopharma CEO strategy agenda

Healthcare and Life Sciences / Article / May 06, 2025
Bioeconomy boom: measuring the impact of biotech innovation

Agriculture and Food / Article / May 02, 2025
How can biopharma companies unlock tangible AI opportunities in clinical development?

Healthcare and Life Sciences / Article / March 20, 2025
Modernizing the biopharma innovation engine

Healthcare and Life Sciences / Article / October 31, 2024
Preparing for the radiopharmaceuticals boom

Health / Article / September 24, 2024
Regenerative commercial models in pharma

Series / August 01, 2024
In conversation with Astrid Scherer

Biopharma R&D Practitioner Voices / Commentary / June 03, 2024
Rethinking the pharma value proposition: from promotion of products to full-system integration

Healthcare and Life Sciences / Article / May 20, 2024
In conversation with Michael May and Matthias Meergans: Germany as a location for pharmaceutical innovation

Biopharma R&D Practitioner Voices / Commentary / January 09, 2024
In conversation with Claudia Dollins on precision medicine

Biopharma R&D Practitioner Voices / Commentary / September 07, 2023
How (bio)pharmaceutical companies can advance their social agendas

Healthcare and Life Sciences / Article / July 28, 2023
In conversation with Axel Wiest on end-to-end mindset in biopharma R&D

Biopharma R&D Practitioner Voices / Commentary / July 24, 2023
Emerging lessons from Japan for pharma commercial transformations

Healthcare and Life Sciences / Article / June 29, 2023
Yes! There is a positive ROI from SCRM

Operations and Performance / Article / March 21, 2023